Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
| ▸ | CTSS | P25774 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.50 |
| ▸ | CTSK | P43235 | 3/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4324281 | 1.00 | CTSL (0.51) | CTSLCTSSHDAC1HDAC6HDAC3 | |
| SCHEMBL2787667 | 0.87 | CTSL (0.44) | CTSLCTSSHDAC1HDAC6HDAC3 | |
| SCHEMBL2787669 | 0.87 | CTSL (0.44) | CTSLCTSSHDAC1HDAC6HDAC3 | |
| SCHEMBL2343173 | 0.85 | TACR3 (0.47) | MME | |
| SCHEMBL2343176 | 0.85 | TACR3 (0.47) | MME | |
| SCHEMBL1928257 | 0.83 | CTSK (0.47) | CTSSCTSK | |
| SCHEMBL1928254 | 0.83 | CTSK (0.47) | CTSSCTSK | |
| SCHEMBL12971777 | 0.83 | ATM (0.55) | CTSLCTSSCTSKCTSBSSTR1 | |
| SCHEMBL1927634 | 0.83 | TACR3 (0.46) | HDAC1HDAC3HDAC2HDAC8MME | |
| SCHEMBL1505365 | 0.83 | ATM (0.55) | CTSLCTSSCTSKCTSBSSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553975-B2 | Farnesyl transferase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2009-06-30 | — | — | US | disclosed |
| US-7323484-B2 | Farnesyl transferase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2008-01-29 | — | — | US | disclosed |
| US-20060252760-A1 | Farnesyl transferase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2006-11-09 | — | — | US | disclosed |
| US-20060079530-A1 | Farnesyl transferase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2006-04-13 | — | — | US | disclosed |
| US-7022704-B2 | 5,6,7, 8-tetrahydro-imidazo-(1,2a)-pyrazine derivative; useful for treating restenosis and tumor | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2006-04-04 | — | — | US | disclosed |
| EP-0904274-B1 | FARNESYL TRANSFERASE INHIBITORS | CONSEILS DE RECH SET D APPLIC (FR) | 2005-05-25 | — | — | EP | disclosed |
| US-6673927-B2 | FOR THERAPY OF TUMOR OR RESTENOSIS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2004-01-06 | — | — | US | disclosed |
| US-20030119864-A1 | Farnesyl transferase inhibitors | BIOMEASURE INCORPORATED, A MASSACHUSETTS CORPORATION | 2003-06-26 | — | — | US | disclosed |
| US-20020013319-A1 | FARNESYL TRANSFERASE INHIBITORS | IPSEN PHARMA S.A.S. (FR) | 2002-01-31 | — | — | US | disclosed |
| EP-0904274-A4 | FARNESYL TRANSFERASE INHIBITORS | BIOMEASURE INC (US) | 1999-12-29 | — | — | EP | disclosed |
| EP-0904274-A1 | FARNESYL TRANSFERASE INHIBITORS | Biomeasure Incorporated (US) | 1999-03-31 | — | — | EP | disclosed |
| WO-1997030053-A1 | FARNESYL TRANSFERASE INHIBITORS | BIOMEASURE INCORPORATED (US) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079530-A1 | Farnesyl transferase inhibitors | FNTB, FNTA, LCAT | CTSL 2244/4885CTSS 2218/4885HDAC1 1907/4885 |
| US-20060252760-A1 | Farnesyl transferase inhibitors | FNTB, FNTA, LCAT | CTSL 2244/4885CTSS 2218/4885HDAC1 1907/4885 |
| US-20030119864-A1 | Farnesyl transferase inhibitors | FNTB, FNTA, LCAT | CTSL 2244/4885CTSS 2218/4885HDAC1 1907/4885 |
| US-20020013319-A1 | FARNESYL TRANSFERASE INHIBITORS | FNTB, FNTA, LCAT | CTSL 2244/4885CTSS 2218/4885HDAC1 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.